Want to see AU:AT1 full AI Analyst Report?
Top Page
Atomo Diagnostics Ltd.
(Sydney:AT1)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.02
▼(-20.00% Downside)
Action:Reiterated
Date:09/06/26
The score is primarily constrained by weak financial quality—ongoing losses, negative gross margin in FY2026, and persistent negative operating/free cash flow—despite strong FY2026 revenue growth and a low-debt balance sheet. Technicals also weigh on the score as the price remains below longer-term moving averages with negative MACD. Valuation provides limited support because earnings are negative and no dividend yield is available.
Positive Factors
Strong FY2026 revenue rebound
The FY2026 revenue rebound shows renewed demand for Atomo’s diagnostic device platform after weaker prior periods. If this growth is sustained through partner orders and repeat demand, it can improve operating leverage and support a path toward stronger financial performance.
Negative Factors
Negative FY2026 gross margin
A negative gross margin means FY2026 revenue was not sufficient to cover reported product costs, undermining the economics of the current sales mix. Unless pricing, production costs, or inventory-related impacts improve, revenue growth may not translate into durable gross profit or operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong FY2026 revenue rebound
The FY2026 revenue rebound shows renewed demand for Atomo’s diagnostic device platform after weaker prior periods. If this growth is sustained through partner orders and repeat demand, it can improve operating leverage and support a path toward stronger financial performance.
Read all positive factors
Atomo Diagnostics Ltd. (AT1) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$14.44M
Dividend YieldN/A
Average Volume (3M)604.89K
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue Growth40.65%
EPS Growth45.45%
CountryAU
Employees85
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding902,432,860
10 Day Avg. Volume292,147
30 Day Avg. Volume604,894
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.82
Price to Sales (P/S)2.64
P/FCF Ratio-4.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$31.96M
Atomo Diagnostics Ltd. Business Overview & Revenue Model
Company Description
Established in 2010 and based in Leichhardt, Australia, Atomo Diagnostics Limited is a global enterprise focused on the innovation and commercialization of medical devices. The company provides swift-result diagnostic tools designed for various ap...
How the Company Makes Money
Atomo Diagnostics makes money primarily by supplying its proprietary rapid test device platforms and associated components to third parties that manufacture and sell completed diagnostic tests. Revenue is generated through sales of physical produc...
Atomo Diagnostics Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.33M | 3.79M | 4.09M | 2.54M | 12.34M |
| Gross Profit | -2.43M | 1.79M | 1.44M | -6.08M | -1.85M |
| EBITDA | -4.26M | -4.25M | -6.12M | -9.00M | -4.72M |
| Net Income | -3.51M | -4.97M | -6.85M | -9.96M | -5.71M |
Balance Sheet | |||||
| Total Assets | 10.83M | 9.28M | 11.38M | 16.47M | 26.62M |
| Cash, Cash Equivalents and Short-Term Investments | 3.71M | 3.22M | 3.69M | 6.47M | 12.97M |
| Total Debt | 373.08K | 185.10K | 141.19K | 254.88K | 340.81K |
| Total Liabilities | 3.12M | 2.30M | 1.29M | 1.68M | 1.81M |
| Stockholders Equity | 7.71M | 6.98M | 10.08M | 14.79M | 24.81M |
Cash Flow | |||||
| Free Cash Flow | -3.40M | -1.99M | -4.70M | -6.25M | -5.11M |
| Operating Cash Flow | -3.37M | -1.96M | -4.69M | -5.85M | -2.81M |
| Investing Cash Flow | -35.32K | -33.89K | -16.08K | -401.28K | -2.31M |
| Financing Cash Flow | 3.81M | 1.46M | 1.87M | -170.75K | 17.61K |
Atomo Diagnostics Ltd. Technical Analysis
Negative
0.02
Price Trends
0.02
Positive
0.02
Negative
0.03
Negative
Market Momentum
>-0.01
Negative
0.46
Positive
266.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AT1, the sentiment is Negative. The current price of 0.02 is equal to the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 0.46 is Positive, neither overbought nor oversold. The STOCH value of 266.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AT1.
Atomo Diagnostics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$45.95M | 209.09 | 0.93% | ― | 18.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$139.43M | -16.54 | -46.84% | ― | ― | 20.40% | |
45 Neutral | AU$14.44M | -3.81 | -48.97% | ― | 40.65% | 45.45% | |
45 Neutral | AU$14.66M | -0.39 | -259.31% | ― | 14.85% | -1.74% | |
43 Neutral | AU$29.36M | -2.73 | -188.06% | ― | 15.58% | 37.17% | |
41 Neutral | AU$46.52M | -2.38 | -62.14% | 0.64% | 12.05% | -31.71% |
* Healthcare Sector Average
AU:AT1
Atomo Diagnostics Ltd.
0.02
-0.01
-46.67%
AU:CMP
Compumedics Limited
0.23
-0.11
-33.33%
AU:IPD
Impedimed Limited
0.01
-0.03
-64.10%
AU:CYC
Cyclopharm Limited
0.37
-0.30
-44.78%
AU:MX1
Micro-X Ltd.
0.04
-0.06
-61.00%
AU:EMV
EMvision Medical Devices Ltd.
1.50
-0.27
-15.25%
Atomo Diagnostics Ltd. Corporate Events
Atomo Diagnostics Issues Cautious Q1 2027 Results Overview
Oct 29, 2026
Atomo Diagnostics has released an overview of its first quarter 2027 results, accompanied by extensive disclaimers that frame the material as general information rather than investment advice. The document stresses that the presentation is incompl...
Atomo boosts HIV and syphilis test pipeline as Q1 revenue surges 140%
Oct 29, 2026
Atomo Diagnostics has expanded its proprietary rapid-testing pipeline through a new memorandum of understanding with Innovation Scientific to develop a fourth-generation HIV rapid test built on its Galileo cassette platform, complementing its exis...
Atomo Diagnostics Strikes Deal to Develop Generation 4 HIV Rapid Test
Oct 28, 2026
Atomo Diagnostics has signed a Memorandum of Understanding with Innovation Scientific to develop and commercialise a Generation 4 HIV rapid assay using Atomo’s Galileo cassette platform. Innovation Scientific will lead further development, a...
Atomo Diagnostics Updates Timing for Q1 FY27 Investor Webinar
Oct 28, 2026
Atomo Diagnostics has rescheduled the start time of its Q1 FY27 quarterly investor webinar to 2 p.m. AEDT on 3 November 2026, to be hosted by chief executive Cheri Walker and financial controller Suzy Elhlou. The company is directing stakeholders ...
Atomo Diagnostics Options Lapse, Tidying Up Capital Structure
Oct 28, 2026
Atomo Diagnostics has reported the cessation of 275,000 listed options (AT1AO) that expired on 22 August 2026 without being exercised or converted. The lapse of these options marginally reduces the pool of potential future equity, leaving existing...
Atomo Diagnostics Options Lapse, Streamlining Capital Structure
Oct 28, 2026
Atomo Diagnostics has confirmed that 2,120,000 options, exercisable at $0.035 and due to expire on 1 July 2027, have ceased following expiry without being exercised. The cessation reduces the company’s pool of outstanding convertible securit...
Atomo Diagnostics Schedules Q1 FY27 Investor Webinar to Boost Stakeholder Engagement
Oct 26, 2026
Atomo Diagnostics has announced a Q1 FY27 quarterly investor webinar to be held on 3 November 2026, hosted by CEO Cheri Walker and Financial Controller Suzy Elhlou. The company is directing investors to pre-register online and to use its dedicated...
Atomo Diagnostics Sets Virtual AGM for 5 November 2026
Oct 1, 2026
Atomo Diagnostics Limited has called its Annual General Meeting for 5 November 2026, to be held virtually via a Zoom webinar at 10:00 a.m. AEDT, reflecting its continued use of remote participation technology for shareholder meetings. The company ...
Atomo Diagnostics Issues FY26 Results Overview Disclaimer
Sep 23, 2026
Atomo Diagnostics Ltd., an ASX-listed medical diagnostics company, develops rapid point-of-care testing solutions for healthcare markets that require fast and accessible diagnostic tools. Its product portfolio is aimed at improving usability and a...
Atomo Diagnostics to Present FY26 Results and Strategy in Investor Webinar
Sep 20, 2026
Atomo Diagnostics will hold a webinar on 24 September 2026, led by new Chief Executive Officer Cheri Walker and Financial Controller Suzy Elhlou, to outline the company’s updated strategic direction and discuss its financial results for the ...
Atomo Diagnostics Files Appendix 4G, Confirms Governance Compliance
Aug 31, 2026
Atomo Diagnostics Limited, an ASX-listed medical diagnostics group, operates in the healthcare sector with a focus on rapid testing solutions and structured corporate governance. The company maintains a board charter and formalised executive arran...
Atomo Diagnostics Issues Cautious FY26 Results Overview
Aug 31, 2026
Atomo Diagnostics has released an overview of its FY26 results, presented as a high‑level information update for investors rather than a detailed financial report. The document emphasises that the material is general in nature, should not be...
Atomo Diagnostics Lifts Revenue and Narrows Annual Loss
Aug 31, 2026
Atomo Diagnostics reported a 41% increase in revenue from ordinary activities to AUD 5.33 million for the year to 30 June 2026, while narrowing its after-tax loss by 29% to AUD 3.51 million. Basic and diluted loss per share improved to 0.425 cents...
Atomo Diagnostics Discloses Director John Kelly’s Exit and Ongoing Shareholding
Aug 19, 2026
Atomo Diagnostics Ltd. has announced that director John Kelly ceased to be a member of the board on 19 August 2026, formalising the change in governance disclosed to the ASX. The notice confirms his substantial direct and indirect shareholdings an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.